Episode
Episode 180 - Ben Zimmer - CEO of Priovant Therapeutics
- Podcast
- The BioHub - by Avetix
- Published
- May 26, 2026
- Duration seconds
- 1676
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-180-ben-zimmer-ceo-of-priovant-therapeutics/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-180-ben-zimmer-ceo-of-priovant-therapeutics.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of The BioHub Podcast , Max sits down with Ben Zimmer, CEO of Priovant Therapeutics. Ben was among the first ten employees at Roivant, helping incubate and launch multiple biotech companies before going on to found Priovant in 2021. Priovant is a clinical-stage biotech focused on developing therapies for severe autoimmune diseases — one of the most active and fast-moving areas in biotech today. In this conversation, we talk about the early days of Roivant, the inspiration behind building Priovant, why autoimmune disease has become such a major focus across the industry, and what it takes to build teams and companies in high-stakes therapeutic areas. We also discuss leadership, decision-making, and what’s next for Priovant.